Physician profile
Anna E Bailey
NPI 1811482250
$831.99
in general payments reported to CMS, 2019-2025
10 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $171 · 2023: $231 · 2024: $176 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $510.70 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $174.84 | 2025 | |
| Lilly USA, LLC | $140.84 | 2024-2025 | Mounjaro |
| Neurocrine Biosciences, INC. | $117.60 | 2022 | |
| Daiichi Sankyo INC. | $115.01 | 2022-2025 | Enhertu, Datroway |
| Alkermes, INC. | $99.82 | 2023 | Lybalvi |
| Seagen INC. | $64.68 | 2023 | Tukysa |
| Astrazeneca Pharmaceuticals LP | $60.08 | 2023-2024 | Enhertu |
| Merck Sharp & Dohme LLC | $24.89 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.63 | 2024 | Iclusig |
| Celgene Corporation | $14.60 | 2024 | Pomalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.